Should Colgate-Palmolive (CL) Look Fully Valued After Q2 Results And Steady Guidance?
What Colgate-Palmolive’s Updated Guidance Means For Investors
Colgate-Palmolive (CL) moved into focus after reporting second quarter 2026 results and keeping its full year outlook. Sales were higher year on year, while net income and earnings per share declined.
See our latest analysis for Colgate-Palmolive.
Colgate-Palmolive’s share price has climbed 19.71% year to date and is up 6.22% over the past 90 days, while the 1-year total shareholder return of 12.53% suggests steady long term momentum despite recent earnings pressure.
If you are comparing Colgate-Palmolive with other potential ideas, this could be a useful moment to widen your watchlist with 21 top founder-led companies
After a near 20% year to date climb and guidance that still points to higher full year earnings, the question for Colgate-Palmolive is simple: Is most of the upside already in the price, or not yet?
Most Popular Narrative: 8% Overvalued
The most followed narrative on Colgate-Palmolive compares a fair value of $86.48 to the last close at $93.00, which implies the stock is pricing in a premium to that framework.
Twenty four times forward Base Business earnings of roughly $3.88 implies about $93 today. This model returns $86.48. The whole difference is structural. When the discount rate exceeds the growth rate, five years at a three point gap costs about 16%. For a slow compounder this method is inherently more conservative than a simple multiple. That is worth knowing before treating the output as a verdict rather than as one lens.
Curious why this narrative lands below the market price. It leans on measured revenue growth, steady margins and a firm exit multiple. The exact mix of those inputs really matters. The details behind that mix are where this valuation gets interesting.
Result: Fair Value of $86.48 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Colgate-Palmolive still faces pressure if North American organic sales remain weak or if another skin health impairment suggests that the earlier charge did not fully capture the problem.
Find out about the key risks to this Colgate-Palmolive narrative.
Another View: Colgate-Palmolive Through A Cash Flow Lens
While the user generated narrative suggests Colgate-Palmolive is overvalued at $93 compared with a fair value of $86.48, the SWS DCF model points in the opposite direction. It estimates fair value at $130.82, which implies the stock trades at a 28.9% discount based on projected cash flows. Which lens do you place more weight on when estimates disagree this much?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Colgate-Palmolive for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
The mixed messages on Colgate-Palmolive might leave you unsure, so consider reviewing the full picture and weighing the 3 key rewards and 3 important warning signs
Looking for more Colgate-Palmolive sized investment ideas?
If Colgate-Palmolive is already on your radar, this can be a moment to broaden your opportunity set with a few focused stock lists built from hard numbers.
- Target steadier potential outcomes by reviewing companies that feature resilient balance sheets and fundamentals with the solid balance sheet and fundamentals stocks screener (49 results).
- Look for potential mispricing by scanning companies that score well on fundamentals and valuation using the 50 high quality undervalued stocks.
- Anchor your portfolio with income candidates by checking out the 9 dividend fortresses before the next set of opportunities changes.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com